A Phase I–II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma

(2009) D Yoshikawa et al.   BRITISH JOURNAL OF CANCER

Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies

(2008) B. R. Tan et al.   ANNALS OF ONCOLOGY

Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial

(2008) O Nehls et al.   BRITISH JOURNAL OF CANCER

Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study

(2008) T André et al.   BRITISH JOURNAL OF CANCER

Patient-Reported Outcomes of Patients With Advanced Biliary Tract Cancers Receiving Gemcitabine Plus Capecitabine: A Multicenter, Phase II Trial of the Swiss Group for Clinical Cancer Research

(2008) Dieter Koeberle et al.   JOURNAL OF CLINICAL ONCOLOGY